Ramon Gomis - Selected Publications#


Palau N, Rebuffat SA, Altirriba J, Piquer S, Hanzu FA, Gomis R*, Barbera A.* (2012) Role of IGFBP-3 in the Regulation of β-Cell Mass during Obesity: Adipose Tissue/β-Cell Cross Talk. Endocrinology 153(1):177-87 (*codirectors)

Altirriba J, Gasa R, Casas S, Ramírez-Bajo MJ, Ros S, Gutierrez-Dalmau A, Ruiz de Villa MC, Barbera A, Gomis R. (2010) The role of transmembrane protein 27 (TMEM27) in islet physiology and its potential use as a beta cell mass biomarker. Diabetologia 53(7):1406-14.

Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJV for the RECORD Study Group (2009) Rosiglitazone evaluated for cardiovascular outcomes in type 2 diabetes: the RECORD clinical trial. Lancet 373(9681):2125-35.

Barceló-Batllori S, Kalko SG, Esteban Y, Moreno S, Carmona MC, Gomis R. (2008) Integration of DIGE and bioinformatics analyses reveals a role of the anti-obesity agent tungstate in redox and energy homeostasis pathways in brown adipose tissue. Mol Cell Proteomics 7(2):378-93

Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JV, for the RECORD Study Group (2007) Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis. N Engl J Med 357(1):28-38.

Barcelo-Batllori S, Corominola H, Claret M, Canals I, Guinovart J, Gomis R. (2005) Target identification of the novel antiobesity agent tungstate in adipose tissue from obese rats. Proteomics 5(18):4927-35.

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290(4):486-94.

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359(9323):2072-7.

Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 345(12):870-8.

Novials A, Rojas I, Casamitjana R, Usac EF, Gomis R. (2001) A novel mutation in islet amyloid polypeptide (IAPP) gene promoter is associated with Type II diabetes mellitus. Diabetologia 44(8):1064-5.

Prof. Ramon Gomis has published approximately 270 papers in high-profile journals such as: The Lancet, The New England Journal of Medicine, JAMA, The Journal of Biological Chemistry, Diabetes, Diabetologia, Endocrinology, Diabetic Medicine, Diabetes Care, Hepatology, The American Journal of Physiology, Transplantation, Obesity, Proteomics, and British Medical Journal, among others. He holds over 5.100 citations (ISI Essential Science Indicator) with an average of 46.41 citations per article and the h-index relative to the field of endocrinology of 3.85.
Imprint Privacy policy « This page (revision-2) was last updated on Thursday, 11. October 2012, 10:42 by Kaiser Dana
  • operated by